Description du projet
Combler les lacunes pour une innovation de pointe dans le domaine des soins de santé
La course de l’Europe pour rester compétitive sur la scène mondiale va recevoir un coup de pouce grâce au lancement du projet NOBEL, financé par l’UE. Reconnaissant le besoin de nanomédicaments innovants et de technologies médicales de pointe, cette initiative ambitieuse vise à révolutionner le secteur. En exploitant le potentiel des nanotechnologies, de la photonique, de la robotique, des matériaux avancés et des technologies de l’information, NOBEL créera un écosystème homogène qui mettra en relation toutes les parties prenantes et éliminera les obstacles tout au long de la chaîne de valeur. Plus précisément, le projet vise à accélérer le développement et l’industrialisation de PME innovantes dans le domaine de la nanomédecine et des technologies médicales. Le résultat attendu est une renaissance de l’économie européenne, générant des emplois précieux et ouvrant la voie à un avenir plus radieux.
Objectif
In order to compete globally, Europe has to innovate and develop nanomedicines and medical technologies with high value and high technological content, well protected IP, and ensuring both a clinical need and commercial opportunities of all new innovations. Technically, this will be achieved by combining elements of key enabling technologies like nanotechnologies, photonics, robotics, advanced materials and information technologies to get smart medical devices and smart nanomedicines. However, the translation of the preclinical proof of concepts to the market via clinical validation, regulatory approval, and approval for reimbursement by the healthcare systems, requires a more integrated and streamlined ecosystem with less barriers between stakeholders and steps. Following their successful experience in the past 12 years of development in nanomedicine and medical technologies, ETPN and the seven other partners of NOBEL are merging their networks to set up a coherent, robust and unique ecosystem where information flow will improve awareness all along the value chain right up to the market access. It develops interactions, cooperation and implementation of complementary actions at local, regional, national, European and even international levels. The building of this ecosystem is based on two main pillars: a joint vision of the strategy for the future (roadmapping) and a high cohesion and interrelationship among the members of the ecosystem. One of the most significant and impactful outputs of this inclusive efficient ecosystem is the tangible acceleration of the development and industrialization of innovative SMEs in nanomedicine and medical technologies. This will impact the renaissance of EU economy by creating jobs and value in Europe. NOBEL will be unique in building the most efficient network of connections and synergies all along the value chain of Nanomedicine and healthcare technologies in Europe.
Champ scientifique
Mots‑clés
Programme(s)
Régime de financement
CSA - Coordination and support actionCoordinateur
75005 Paris
France